The worldwide increased prevalence of allergic diseases, and especially of respiratory allergy, is paralleled by increased health costs. This requires consideration of the cost to efficacy ratio of the available treatment to identify the optimal choice.
Ariano, R., Berto, P., Incorvaia, C., Di Cara, G., Boccardo, R., La Grutta, S., et al. (2009). Economic evaluation of sublingual immunotherapy vs. symptomatic treatment in allergic asthma. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 103(3), 254-259 [10.1016/S1081-1206(10)60190-1].
Economic evaluation of sublingual immunotherapy vs. symptomatic treatment in allergic asthma
LA GRUTTA, Stefania;
2009-01-01
Abstract
The worldwide increased prevalence of allergic diseases, and especially of respiratory allergy, is paralleled by increased health costs. This requires consideration of the cost to efficacy ratio of the available treatment to identify the optimal choice.File in questo prodotto:
File | Dimensione | Formato | |
---|---|---|---|
(34) Ariano_Annals2009_Economic evaluation of sublingual.pdf
accesso aperto
Dimensione
167.1 kB
Formato
Adobe PDF
|
167.1 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.